DBV reports Q2 net loss $33.1M, cash $66.2M, going concern doubt; VITESSE on track

DBV Technologies S.A.

2024-Q2 EPS reported -$0.63 revenue$2,568,000

Q2 net loss of $33.1M (US GAAP), basic EPS -$0.34 vs -$0.26 in Q2 2023.
Cash and equivalents $66.2M at June 30, 2024, down from $141.4M at Dec 31, 2023; cash runway extended into Q1 2025.
Substantial doubt about going concern; expects to need additional capital to fund operations.
VITESSE Phase 3 enrollment in 4-7-year-olds on track to complete screening by end of Q3 2024.
Submitted labeling proposal to FDA for COMFORT Toddlers (1-3-year-olds) using EPITOPE data to identify responders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.